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Introduction: This study investigated how total gastrectomy (TG), along with memories of cancer, affect
the subjective wellness of survivors long after surgery. Rational approaches for effectively improving the
quality of life (QoL) of these survivors were suggested.
Methods: Between 2008 and 2013, QoL data of gastric cancer patients who underwent a curative TG,
were obtained at 5-year postoperative follow-up visits (5-year survivors) and at visits beyond 5 years
(long-term survivors). The control groups for these survivor groups were constructed from volunteers
who visited our health-examination center for annual medical checkups. The Korean versions of the
European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire Core 30 (QLQ-
C30) and the gastric cancer speciﬁc module, the EORTC QLQ-STO22, were used to assess QoL.
Results: Five-year survivors showed worse QoL compared to the control group in role functioning, social
functioning, nausea/vomiting, appetite loss, ﬁnancial difﬁculties, reﬂux, eating restrictions, taste, and
body image, and better QoL in the emotional and cognitive functioning scales. In long-term survivors,
deterioration in QoL were still apparent in ﬁnancial difﬁculties, reﬂux, and eating restrictions, while QoL
differences in the remaining scales had diminished.
Discussion: Surviving 5 years after TG does not result in living in a carefree state in terms of QoL. After 5
postoperative years, survivors still need extended care for deteriorated QoL indicators due to symp-
tomatic, behavioral, and ﬁnancial consequences of surgery.
Conclusion: While relevant clinical and institutional approaches are required for corresponding declines
in QoL, such efforts must extend beyond 5 postoperative years.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The ultimate goal of the quality of life (QoL) assessment of
cancer patients is to restore them to a healthy period as quickly as
possible. In general, efforts for QoL improvement are well justiﬁed
provided they do not have ill effects on the survival of cancer pa-
tients. In patients with gastric cancer in the upper part of the
stomach, total gastrectomy (TG) is considered the best surgical
choice. [1,2] Although there have been some attempts to preserve a
food reservoir by a proximal gastrectomy [3e6] or by a TG followed
by jejunal pouch reconstruction [7e9], these procedures have
never gained much popularity. However, undergoing a TG for
gastric cancer at the upper part of the stomach is well justiﬁed due
to its curativeness and survival rates. Nonetheless, an inevitable
consequence is a deterioration in QoL from a restricted foodby Elsevier Ltd. All rights reservedreservoir. Moreover, having the stomach completely removed by TG
results in not only problems related to a restricted food reservoir,
but also problems related to vitamin B12 deﬁciency, which neces-
sitates supplementation for life [10,11].
In general, the 5-year postoperative point is often regarded as a
turning point in the ﬁght against cancer even though being cancer-
free after surviving 5 postoperative years represents a somewhat
misleading interpretation of 5-year survival. Because a TG involves
the total loss of a gastric food reservoir and a need for lifetime
vitamin B12 supplementation, the functional and physiological
changes from a TG last beyond 5 years of survival after surgery. Yet,
regarding QoL, one may objectively be unwell and, at the same
time, subjectively be well, and vice versa [12].
Several studies report QoL in patients shortly after TG in which
QoL has declined [13]. Other studies report QoL after accumulation
of data for signiﬁcantly longer periods [14,15]. Nonetheless, QoL of
those shortly after TG has been included in their analyses, and QoL
deteriorations of those after TG have been reported. There has been.
Table 1
Scales of EORTC QLQ-C30 and EORTC QLQ-STO22.
EORTC QLQ-C30
Global health status/QoL scalea
Functional scalesa
Physical functioning
Role functioning
Emotional functioning
Cognitive functioning
Social functioning
Symptom scales/itemsb
Fatigue
Nausea and vomiting
Pain
Dyspnea
Insomnia
Appetite loss
Constipation
Diarrhea
Financial difﬁculties
EORTC QLQ-STO22b
Dysphagia
Pain
Reﬂux
Eating restrictions
Anxiety
Dry mouth
Taste
Body image
Hair loss
QoL, quality of life; EORTC QLQ, European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire.
a A higher score represents a better QoL.
b A higher score represents a worse QoL.
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measures, including the Short-Form 36 and the 15D instrument
[16]. Those after TG performed almost as well as the healthy control
groups, except for sleeping, bladder/bowel functions, and diarrhea.
However, the consequent strategies for its effective management
have not been discussed in depth. While few attempts have been
made to assess QoL in patients after TG using various QoL measures
[17], cancer-speciﬁc QoL measures, such as the Functional Assess-
ment of Cancer-General (FACT-G), and the European Organization
for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire Core 30 (QLQ-C30), have been developed [18,19]. We
used the EORTC QLQ-C30 and its gastric cancer speciﬁc module, the
EORTC QLQ-STO22, to assess the QoL of long-term survivors after
TG.
This study aimed to investigate how TG, along with memories of
cancer, affects the subjective wellness of survivors long after sur-
gery, and suggests rational approaches to improve the QoL in sur-
vivors after TG. We discuss the subjective wellness of survivors
after TG by assessing the QoL of those who have survived 5 years
and beyond after TG and by making comparisons with estimations
of QoL from healthy volunteers.
2. Methods
2.1. Study participants and design
This study was approved by our institutional review board. QoL
data on gastric cancer patients who underwent a curative total
gastrectomy were obtained during their ﬁfth annual follow-up visit
after surgery between 2008 and 2013. Patients aged 45e70 years
were included. QoL data of 155 patients were available. The
exclusion criteriawere as follows: (1) past history of gastric surgery,
(2) combined resection or other additive procedures, and (3) co-
morbidities that could inﬂuence QoL. Seven patients who under-
went TG for remnant gastric cancer after distal subtotal gastrec-
tomy were excluded. A patient who underwent a combined
resection (distal pancreatectomy) was also excluded. Four patients
were excluded due to other malignancies (1), or cerebrovascular
(1), neurologic (1), or pulmonary (1) conditions. Of 155 patients,
143 patients were included and categorized as 5-year survivors.
During the same period, the QoL data of long-term survivors
(beyond 5 years) after TG were collected on their visits for regular
follow-ups or vitamin B12 supplementations. Patients between
the ages of 45 and 70 years were included and QoL data from 44
individuals were available. Identical exclusion criteria were
applied and 5 patients were excluded due to remnant gastric
cancer (3), combined resection (1), and jejunal interposition (1). Of
these 44 patients, 39 were included and categorized as long-term
survivors.
The control groups for the 5-year survivors and the long-term
survivors were constructed from volunteers who visited our
health-examination center for annual medical checkups. QoL data
were obtained upon their initial visit. Those with extensive medical
histories or abnormal test results that necessitated medical atten-
tion were excluded. QoL data from 80 age- and gender-adjusted
healthy volunteers were used to estimate healthy QoL indicators
of 143 5-year survivors. Those from 39 age- and gender-adjusted
healthy volunteers were used to estimate healthy QoL indicators
of 39 long-term survivors.
2.2. QoL assessments
The EORTC has developed a set of QoL measures for cancer pa-
tients in the form of a multi-dimensional and self-administrated
questionnaire. It has been designed to be applicable across arange of cultural settings, and translated versions into different
languages are available. The validated Korean version of the EORTC
QLQ-C30 and its gastric cancer speciﬁc module, the EORTC QLQ-
STO22, were used to assess QoL [20]. The EORTC QLQ-C30 is
composed of a global health status/QoL scale, ﬁve functional scales,
and nine symptom scales/items. The EORTC QLQ-STO22 comprises
nine symptom scales/items. QoL is represented by a score ranging
from 0 to 100 for each scale. Detailed structures and interpreta-
tional guidelines of each tool are provided in Table 1.2.3. Statistical analysis
The QoL outcomes of 5-year survivors and long-term survivors
were compared to corresponding estimated healthy QoL scores.
The QoL of 5-year survivors and that of long-term survivors were
compared as well.
The demographic values were compared using a Student's t-test
and a chi-square test. A Student's t-test was used to make QoL
comparisons between groups. A p-value of less than 0.05 was
considered statistically signiﬁcant. All statistical analyses were
conducted using the Statistical Package for Social Science version
20.0 (IBM Corporation, Armonk, NY, USA).3. Results
3.1. Characteristics of study participants
The 5-year survivor group was comprised of 105 men and 38
women with a mean age of 59.6 ± 6.8 years (Table 2). The corre-
sponding healthy control group was comprised of 57 men and 23
women with a mean age of 59.7 ± 6.6 years. There were no sta-
tistically signiﬁcant differences of gender and age between them
(p ¼ 0.727, p ¼ 0.888).
Table 2
Characteristics of 5-year survivors and long-term survivors after total gastrectomy, and estimated healthy controls.
5-year survivors Long-term (>5 years) survivors p-valueb
Survivor group Healthy control p-value Survivor group Healthy control p-value
N (%) N (%) N (%) N (%)
Age, years 0.996 0.969 0.348
45e50 13 (9.1) 7 (8.8) 5 (12.8) 5 (12.8)
51e60 62 (43.4) 35 (43.8) 12 (30.8) 13 (33.3)
61e70 68 (47.6) 38 (47.5) 22 (56.4) 21 (53.8)
Gender 0.727 1.000 0.040
Female 38 (26.6) 23 (28.8) 17 (43.6) 17 (43.6)
Male 105 (73.4) 57 (71.3) 22 (56.4) 22 (56.4)
Residential environment 0.194 0.126 0.518
Metropolitan 95 (66.4) 47 (58.8) 27 (69.2) 23 (59.0)
Urban 16 (11.2) 16 (20.0) 2 (5.1) 8 (20.5)
Rural 32 (22.4) 17 (21.3) 10 (25.6) 8 (20.5)
Residential district 0.584 0.644 0.639
Local 138 (96.5) 76 (95.0) 37 (94.9) 36 (92.3)
Neighboring 5 (3.5) 4 (4.0) 2 (5.1) 3 (7.7)
Distant 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Linear distance to hospital, km 0.659 0.147 0.575
20 101 (70.6) 53 (66.3) 29 (74.4) 23 (59.0)
20e50 24 (16.8) 12 (15.0) 8 (20.5) 7 (17.9)
51e100 16 (11.2) 13 (16.3) 2 (5.1) 8 (20.5)
>100 2 (1.4) 2 (2.5) 0 (0.0) 1 (2.6)
Stagea e e 0.246
I 101 (70.6) e e 21 (53.8) e e
II 29 (20.3) e e 13 (33.3) e e
III 9 (6.3) e e 3 (7.7) e e
IV 4 (2.8) e e 2 (5.1) e e
Extent of lymphadenectomy e e 0.612
<D2 2 (1.4) e e 1 (2.6) e e
D2 141 (98.6) e e 38 (97.4) e e
History of chemotherapy e e 0.025
No 110 (76.9) e e 23 (59.0) e e
Yes 33 (23.1) e e 16 (41.0) e e
History of early complications e e 0.801
No 137 (95.8) e e 37 (94.9) e e
Yes 6 (4.2) e e 2 (5.1) e e
N, number of participants.
Bold font denotes a signiﬁcant difference between groups.
a Stage grouping according to the 6th edition of the Union for International Cancer Control (UICC) classiﬁcation.
b Compared between 5-year survivors and long-term survivors.
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surgery was 89.3 ± 28.3 months (range: 66e201 months). There
were 22 men and 17 women with a mean age of 60.4 ± 7.2 years.
The corresponding healthy control group of 22 men and 17 women
has a mean age of 60.4 ± 7.2 years and the gender distribution and
age were not statistically different between the groups (p ¼ 1.000,
p ¼ 1.000).
When comparisons were made between 5-year survivors and
long-term survivors, the mean age was not signiﬁcantly different.
However, the gender distribution was signiﬁcantly different be-
tween them (p ¼ 0.040). Six of the 5-year survivors experienced
early postoperative complications (four cases of intra-abdominal
ﬂuid collection requiring percutaneous drainage and two cases of
surgical wound problems managed by dressing), and two of the
long-term survivors had early postoperative complications (two
cases of intra-abdominal ﬂuid collection requiring percutaneous
drainage).3.2. QoL of 5-year survivors as compared to the estimated QoL of
healthy volunteers
At the 5-year postoperative period, the global health status/QoL
was not signiﬁcantly different between cancer survivors and the
healthy control group (Table 3). However, 5-year survivors showed
signiﬁcantly worse QoL in a large number of scales (e.g., rolefunctioning, social functioning, nausea and vomiting, appetite loss,
ﬁnancial difﬁculties, reﬂux, eating restrictions, taste, and body
image), as compared to the healthy control group (Fig. 1). Better
QoL in 5-year survivors was revealed in emotional functioning
(p ¼ 0.007) and cognitive functioning (p ¼ 0.008).
3.3. QoL of long-term survivors as compared to the estimated QoL
in healthy volunteers
The global health status/QoL was not signiﬁcantly different be-
tween long-term survivors and the healthy control group. However,
signiﬁcantly worse QoL in ﬁnancial difﬁculties (p ¼ 0.001), reﬂux
(p ¼ 0.049), and eating restrictions (p ¼ 0.014) were still seen in
long-term survivors. The better QoL in emotional and cognitive
functioning scales, as seen in the 5-year survivors, were not
revealed in the long-term survivors.
3.4. QoL comparisons between 5-year survivors and long-term
survivors
Signiﬁcant differences in QoL were not revealed in most of the
scales, including global health status/QoL (p ¼ 0.335). However,
long-term survivors revealed signiﬁcantly worse QoL in emotional
functioning, as compared to the 5-year survivors (p ¼ 0.010). A
similar pattern was revealed in cognitive functioning and ﬁnancial
Table 3
Comparisons of QoL between 5-year and long-term survivors after TG, and estimated healthy controls, as assessed by the Korean version of the EORTC QLQ-C30 and QLQ-
STO22.
5-year survivors Long-term (>5 years) survivors p-valuec
Survivor group Healthy control p-value Survivor group Healthy control p-value
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
EORTC QLQ-C30
Global health status/QoLa 135 66.2 (26.2) 77 63.3 (21.8) 0.418 38 61.4 (29.2) 39 63.7 (24.4) 0.711 0.335
Functional Scalesa
Physical functioning 141 81.7 (17.0) 80 82.4 (14.9) 0.762 39 77.9 (16.4) 39 82.2 (13.2) 0.205 0.212
Role functioning 141 81.9 (20.7) 80 88.1 (16.2) 0.021 39 84.2 (20.2) 39 88.9 (13.4) 0.231 0.542
Emotional functioning 141 82.8 (17.8) 80 76.0 (18.4) 0.007 39 74.0 (21.7) 39 73.3 (20.3) 0.882 0.010
Cognitive functioning 141 82.5 (16.6) 80 76.0 (18.1) 0.008 39 75.6 (23.5) 39 75.2 (20.5) 0.932 0.094
Social functioning 141 82.2 (21.9) 80 88.1 (18.8) 0.042 38 80.3 (23.8) 39 85.9 (19.3) 0.258 0.644
Symptom Scales/itemsb
Fatigue 142 31.6 (21.4) 80 31.8 (21.3) 0.948 39 35.9 (23.4) 39 33.5 (21.0) 0.632 0.279
Nausea and vomiting 143 15.2 (21.7) 80 9.6 (14.0) 0.021 39 13.7 (17.5) 39 11.5 (14.4) 0.557 0.697
Pain 141 14.2 (20.4) 80 16.7 (20.4) 0.385 39 15.4 (23.4) 39 16.7 (19.5) 0.793 0.753
Dyspnea 140 13.1 (21.4) 80 13.7 (18.9) 0.820 39 18.8 (22.7) 39 17.1 (21.5) 0.733 0.148
Insomnia 141 19.9 (25.5) 80 20.0 (26.3) 0.969 37 20.7 (30.8) 39 15.4 (20.0) 0.376 0.861
Appetite loss 141 16.1 (26.3) 78 9.0 (19.1) 0.023 39 18.8 (32.3) 38 11.4 (22.3) 0.245 0.587
Constipation 140 12.6 (22.1) 80 17.1 (23.1) 0.157 39 18.8 (25.1) 39 17.9 (21.4) 0.872 0.135
Diarrhea 138 25.4 (24.0) 78 20.5 (24.2) 0.156 38 30.7 (33.2) 38 24.6 (25.3) 0.368 0.359
Financial difﬁculties 141 18.7 (24.4) 79 6.3 (14.2) <0.001 39 28.2 (32.0) 38 7.0 (15.8) 0.001 0.091
EORTC QLQ-STO22b
Dysphagia 141 13.4 (16.1) 80 10.3 (10.4) 0.090 39 16.2 (15.5) 39 11.3 (11.4) 0.110 0.327
Pain 141 20.4 (23.7) 80 16.4 (19.2) 0.196 39 22.1 (19.1) 39 21.2 (20.8) 0.838 0.686
Reﬂux 141 17.3 (18.9) 80 11.8 (17.6) 0.033 39 23.4 (16.9) 39 14.8 (20.6) 0.049 0.073
Eating restrictions 142 20.3 (20.8) 80 6.9 (12.3) <0.001 39 20.1 (23.1) 39 9.0 (14.3) 0.014 0.963
Anxiety 141 29.0 (22.5) 80 24.2 (18.6) 0.110 39 31.8 (27.1) 39 21.9 (18.1) 0.064 0.517
Dry mouth 137 22.1 (26.0) 79 28.3 (27.8) 0.105 39 23.9 (30.5) 39 28.2 (28.1) 0.522 0.716
Taste 141 10.6 (21.6) 80 5.8 (13.8) 0.045 39 12.0 (19.5) 39 8.5 (16.6) 0.407 0.729
Body image 140 29.3 (28.7) 80 14.2 (21.1) <0.001 38 28.9 (32.1) 39 17.1 (24.0) 0.070 0.950
Hair loss 52 32.1 (24.7) 40 43.3 (36.4) 0.096 16 39.6 (30.4) 18 33.3 (30.2) 0.552 0.316
QoL, quality of life; TG, total gastrectomy; EORTC QLQ, European Organization for Research and Treatment Quality of Life Questionnaire; N, number of responders; SD, standard
deviation.
Bold font denotes a signiﬁcant difference between groups.
a A higher score represents a better QoL.
b A higher score represents a worse QoL.
c Compared between 5-year survivors and long-term survivors.
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p ¼ 0.091).4. Discussion
When we assessed the QoL of 5-year survivors and long-term
survivors after a TG, QoL deteriorations were still apparent in (1)
multiple scales in 5-year survivors and (2) three scales in long-term
survivors. The QoL of the 5-year survivors were heavily inﬂuenced
by surgery and the past memory of malignancy. They revealed
worse QoL in role and social functioning scales inwhich TG patients
still suffered from limitations in working and performing daily ac-
tivities, hobbies, and family/social activities. They exhibited worse
QoL related to symptoms, such as nausea, vomiting, reﬂux, appetite
loss, and taste abnormalities. They also suffered impaired QoL from
restricted eating habits, poor body image, and ongoing ﬁnancial
difﬁculties. While surviving 5-years after surgery is often regarded
as a turning point in the ﬁght against cancer, in terms of QoL, sur-
vivors after a TG still have persistent needs for QoL management.
While these limitations warrant ongoing clinical and institu-
tional supports for TG patients at the 5-year postoperative period,
the QoL of survivors beyond the 5-year postoperative period was
not different from that of healthy populations in most of the scales,
except ﬁnancial difﬁculties, reﬂux, and eating restrictions. Impaired
QoL diminishes as patients survive longer after a TG; this may be
represented as an upward convergence of QoL of survivors to that of
the healthy population. However, our attention must be directedtoward impaired QoL in the three scales that did not diminish over
time.
The reﬂux scale assesses QoL related to the actual presentation
or associated symptoms of acid/bile regurgitation and belching. The
eating restriction scale assesses not only the actual symptoms but
also difﬁculties related to changes in eating habits because of the
restricted food reservoir. Our study revealed that even though QoL
deterioration from actual nausea and vomiting had diminished
beyond the 5-year postoperative period, declines in QoL from
symptoms, such as reﬂux and early satiety, persisted and affected
long-term survivors. Moreover, both symptoms, and the changes in
eating habits to reduce such symptoms, resulted in declines in QoL
that lasted beyond the 5-year postoperative period.
QoL deterioration in ﬁnancial difﬁculties beyond the 5-year
postoperative period also deserves our attention in two aspects.
The ﬁrst aspect concerns all survivors with different types of cancer
and its treatment. While the patients survived 5 years after surgery,
the notion of being cancer-free after surviving 5 years is misleading,
and minimal, yet persistent surveillance is recommended beyond
the 5 postoperative years. In the society where this study was
conducted, cancer patients' out-of-pocket payments are minimized
by extended coverage from national health insurance during the 5
years after the cancer diagnosis; thus, there would be a personal
ﬁnancial burden for cancer surveillance after that period. The sec-
ond aspect concerns only survivors following a TG, which requires a
lifetime of B12 supplementation [10,11]. Unlike cancer surveillance,
which may be omitted depending on personal economic status,
survivors are not likely to have choices regarding vitamin B12
Fig. 1. QoL scales of signiﬁcant differences between groups of 5-year and long-term survivors after TG and estimated healthy controls, as assessed by the Korean version of the
EORTC QLQ-C30 and QLQ-STO22. A better QoL is represented by a higher score in the global health status/QoL and functional scales of the EORTC QLQ-C30 (A) and by a lower score
in symptom scales/items of the EORTC QLQ-C30 and QLQ-STO22 (B). *p < 0.05; QoL, quality of life; TG, total gastrectomy; EORTC QLQ, European Organization for Research and
Treatment Quality of Life Questionnaire.
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sequent disabilities in personal activities.
In terms of restoring QoL, our study revealed that survivors 5-
years after a TG still need symptom management, dietary control,
preservation of self-esteem, maintenance of social competitiveness,
and ﬁnancial support. Moreover, our study justiﬁes further
extended efforts in symptom management of reﬂux, early satiety,
dietary control, and ﬁnancial support for the effective management
of QoL in long-term survivors. Creation of a food reservoir during
surgery could be a potential alternative by eliminating the funda-
mental source of persistent QoL deteriorations related to reﬂux,
early satiety, and stressors from dietary controls. It must be noted,
however, that the role of proximal gastrectomy in the improvement
of QoL is still controversial [21], and that pouch reconstruction after
TG has yet to come into wide practice despite some positive out-
comes [22]. In order to promote the creation of a food reservoir in
clinical practice, further evidence of its safety and convenience, and
the beneﬁts to QoL are needed.
An explanationmay be required for the unexpected outcomes of
superior QoL in emotional and cognitive functioning in 5-year
survivors. The emotional functioning scales assessing QoL related
to tensed, worried, irritable, and depressed moods. The cognitive
functioning scale assesses QoL regarding difﬁculties related to
concentrating and remembering. We believe that these emotional
and cognitive functioning scales are related to general, undeﬁned
health concerns, which were not focused on during the ﬁght
against cancer [12]. The long-term survivors, on the other hand,
revealed comparative QoL in these scales without statisticallysigniﬁcant differences. This may represent a downward conver-
gence of QoL in survivors to that of healthy populations, in which
the patient transforms from a cancer patient into an individual
concerned about their health, as they survive longer.
A limitation of this study is that we are not able to suggest the
valid duration of QoL management regarding ﬁnancial difﬁculties,
reﬂux, and eating restrictions. There also exists a limitation related
to the sample size of the long-term survivors. The number of long-
term survivors, compared to 5-year survivors, was likely much
smaller due to redistribution of patients to community hospitals
after 5 years of survival. The mailing survey may have yielded a
larger group of long-term survivors. However, mailing surveys
inevitably lack data related to the actual health status of survivors,
and proper exclusion of those with co-morbidities may be impos-
sible. The representability of healthy controls may well be an issue
of great importance, as well. Although our group of healthy controls
seemed to originate from similar environments as our survivors, its
QoL would not represent the healthy QoL of those in different re-
gions or societies. Thus, construction of an individualized healthy
control of validity for survivors from different regions is mandatory.
Even with these limitations, this study is signiﬁcant for two
reasons. The ﬁrst is that it revealed delayed convergences (down-
ward convergences of emotional functioning and cognitive func-
tioning and upward convergences of role functioning, social
functioning, nausea and vomiting, appetite loss, taste, and body
image), requiring QoL management for an extended period beyond
5 postoperative years. The second is it provided a scientiﬁc basis for
the management of QoL for even longer or lifetime periods in scales
S.S. Lee et al. / International Journal of Surgery 12 (2014) 700e705 705with failed convergences (e.g., ﬁnancial difﬁculties, reﬂux, and
eating restrictions). Future research involving serial QoL assess-
ments beyond 5 years after a TG may enable health care providers
to construct evidence-based, long-term, or life-long strategies for
the management of the QoL of cancer survivors after TG.
When a cancer patient survives 5 years after a TG, it does not
provide for a carefree state in terms of QoL. At the 5-year post-
operative period, patients who have had a TG are still in need of
extended care for deferred QoL indicators from symptomatic,
behavioral, and ﬁnancial consequences of surgery. Moreover, con-
cerns related to ﬁnancial status, reﬂux, early satiety, and ongoing
needs for dietary controls have constant, adverse effects on survi-
vors' QoL. Therefore, extension of relevant efforts beyond 5 years
after TG is not an overtreatment but a well-justiﬁed practice. Pro-
vision of reasonable, extended clinical/institutional support for
relevant periods is necessary.
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